Strong Vyvanse Sales Boost Shire’s First Quarter

Shire posted another strong set of results yesterday, with a 20 percent rise in first-quarter earnings, just beating market expectations, and their attention-deficit hyperactivity disorder (ADHD) treatments and rare disease drugs once again performing well. Shire, whose development has outstripped the industry thanks to its acquisitive strategy, reported earnings per ADS (American Depositary Share) of

Continue Reading